The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Por Van Roy, Maarten, Ververken, Cedric, Beirnaert, Els, Hoefman, Sven, Kolkman, Joost, Vierboom, Michel, Breedveld, Elia, ‘t Hart, Bert, Poelmans, Sofie, Bontinck, Lieselot, Hemeryck, Alex, Jacobs, Sandy, Baumeister, Judith, Ulrichts, Hans
Publicado no Arthritis Res Ther (2015)

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

Por Huet, Heather A, Growney, Joseph D, Johnson, Jennifer A, Li, Jing, Bilic, Sanela, Ostrom, Lance, Zafari, Mohammad, Kowal, Colleen, Yang, Guizhi, Royo, Axelle, Jensen, Michael, Dombrecht, Bruno, Meerschaert, Kris RA, Kolkman, Joost A, Cromie, Karen D, Mosher, Rebecca, Gao, Hui, Schuller, Alwin, Isaacs, Randi, Sellers, William R, Ettenberg, Seth A
Publicado no MAbs (2014)